Autoimmune lymphoproliferative syndrome type Ia (ALPS Ia) is caused by mutations in the CD95/Apo-1/Fas (TNFRSF6) gene, which lead to a defective CD95 ligand (CD95L)-induced apoptosis. Soluble CD95 (sCD95) has been suggested to play an important role in the pathogenesis of diverse autoimmune and malignant diseases by antagonizing CD95L. Here we evaluate a family with four in five of its members harboring an ex-6 -3C->G mutation that affects the splice cis regulatory region (cctacag/ex-6 ->cctagag/ex-6) of the CD95 gene. The mutation causes skipping of exon-6, which encodes the transmembrane region of CD95, and thereby leads to an excessive production of sCD95 in all four affected individuals. The mutation is associated with a low penetrance of disease phenotype and caused mild and transient ALPS in one male patient whereas all other family members are completely healthy. In all family members with the mutation we found that the cell surface expression of CD95 was low and the activated T cells were resistant to CD95-induced apoptosis. Unexpectedly, excessive production or addition of sCD95 had no effect on the CD95-induced apoptosis in diverse cells. In contrast, increasing the surface expression of CD95 was able to correct the defect in apoptosis.
Introduction
CD95 (Fas, Apo1, TNFRSF6) is a transmembrane receptor belonging to the tumor necrosis factor superfamily 1 . Upon CD95 ligand (CD95L) stimulation, CD95 can induce programmed cell death (also referred to as apoptosis). Apoptosis is crucial for homeostasis of the immune system [2] [3] [4] . It can downregulate an immune response after the elimination of antigens; it is also involved in removing autoreactive or futile cells and in extinguishing malignant lymphatic cells or their genetically altered precursors 5;6 .
Recently, defects in genes regulating apoptosis have been discovered causing the clinical picture of Autoimmune Lymphoproliferative Syndrome, ALPS [7] [8] [9] , or an ALPS-like clinical manifestation 10 . ALPS (also called Canale-Smith syndrome 6;10-12 ) is characterized by recurrent or more often chronic, benign, sometime massive lymphoadenopathy;
splenomegaly of early onset; autoimmune phenomena such as thrombocytopenia or hemolytic anemia; and less frequently, malignant lymphoma 5;6 . In addition, CD4/CD8 double negative, α/β receptor-positive T cells are often present. Further immunophenotypic characteristics have been detailed previously 13 . However, even within one family, members that carry the same genetic defect can have diverse clinical phenotypes, including mild, reversible symptoms if any, severe autoimmune phenomena, and/or different malignancies 5 . Furthermore, many patients come up with improvement of their symptoms when they grow older. According to the OMIM nomenclature, several types of ALPS exist 7;9;12;14-20 : ALPS Ia, the most common form, is associated with mutations in the CD95 gene, in ALPS Ib the CD95L gene is affected, whereas mutations in the caspase-10 gene lead to ALPS II, and cases without defined mutations are termed ALPS III. Other authors refer to the latter form as ALPS-like disease (ALD) 10 . ALPS induced by somatic mutations has also been described 21 .
The majority of ALPS Ia cases is due to mutations in the death domains of the CD95
gene. The penetrance of its phenotypes is high because the mutant proteins exert dominant-negative effects on function of the wild-type CD95 protein. In contrast, there are forms of ALPS Ia with low-penetrance, which have been shown to be due to
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Pro-and anti-apoptotic stimuli must be balanced carefully in the immune system in order to achieve effective homeostasis without causing "collateral tissue damage".
Alternative splicing plays a critical role in regulation of apoptosis under many circumstances [23] [24] [25] [26] [27] [28] . It has previously been strongly suggested that sCD95, a translational product of alternatively spliced isoforms of CD95 mRNA that lacks exon-6, can block apoptosis through CD95 [29] [30] [31] [32] [33] [34] . CD95 exon-6 encodes the transmembrane domain and is therefore needed for cellular expression of the protein. This soluble form of CD95 has been postulated to bind and thus to neutralize CD95L. At the CD95 pre-mRNA level, the inclusion of exon-6 is upregulated by the binding of TIA-1 or TIAR to the U rich region in intron-5 directly downstream of the exon-5 ( fig.1 ) 33 . This process facilitates the 5'splice-site recognition and the selection of the splice partner at the 3'end of the intron-5. We here describe for the first time four members of a family, who carry a heterozygous double "ag" in intron-5 directly upstream of exon 6. This mutation alters the 3' splice-recognition site of the intron and therefore causes a defect in splice regulation, leading to excessive production and secretion of sCD95. Unexpectedly, such excessive sCD95 serum levels can be compatible with excellent health. 
Purification of genomic DNA
For isolation of DNA, the QIAamp® kit (Qiagen, Hilden, Germany) was used according to the protocol provided. Briefly, 200 µL of whole blood were lysed by proteinase K, nucleic acids denatured by addition of ethanol (96%), absorbed to the silica membrane provided, washed, and eluted. The A 269/280 ratio was 1.5-1.8, and the DNA yield was 4-6 µg in 200 µL of Tris, EDTA (TE) buffer.
mRNA isolation and cDNA synthesis
For the analysis of the CD95 mRNA from peripheral mononuclear cells (PBMC) and from EBV transformed B cells, the Dynabeads  mRNA direct kit (Dynal, Oslo, Norway) and the Superscript TM preamplification system for first strand cDNA synthesis (GibcoBRL, Eggenstein, Germany) were used according to the instruction manuals.
Briefly, 4x10 6 cells were lysed, homogenized, and incubated with oligo (dT) 25 beads.
Using magnetic separation, washing steps included 2x LiDS and 3x standard washing buffer. After elution, 20µL of mRNA solution were incubated with oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer, polymerase chain reaction (PCR) buffer including MgCl 2 , dNTP mix, Dithiothreitol (DTT), and superscript II reverse transcriptase for 50 min at 42 0 C.
PCR conditions
Thermo stable DNA polymerase, "Amplitaq Gold with Gene Amp R " and 10x buffer containing 15mM MgCl 2 were purchased from Perkin Elmer (Weiterstadt, Germany). 10 µL of the buffer were mixed with 5 µL dNTPs (10mM of each), 5 µL of each primer (100 ng, tab.1, fig.1 by spectrometry (at 260 nm).
Real time TaqMan TM PCR (quantitative PCR)
Primers and probes (tab.1, fig.1 ) were designed using the primer express software 
Cycle sequencing
The PE/ABI BigDye TM terminator-cycle-sequencing kit was purchased from Perkin Elmer (Weiterstadt, Germany) and was used to determine the sequence of the CD95 gene according to the provided protocol. Briefly, after mixing of 1 µL PCR product (100 ng DNA) with 1 µL primer (100ng), 2 µL terminator ready reaction mix (containing Mg 2+ , pyrophosphatase, and polymerase) and ddH 2 O to a final reaction volume of 10 µL, the following cycle conditions were applied: 25 x: 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 minutes, 4°C forever (Trio Thermoblock, Biometra): The sequence was determined using a Sequagel 4.5% (National Diagnostics, Atlanta, GA) and a PE/ABI 377 automatic sequencer (Foster City, CA, USA). The sequences were aligned with both the standard sequence and the sequence of a healthy control using the ABI 377 sequence navigator software. Aberrant sequences were always confirmed on both DNA strands and in a second DNA sample to avoid PCR artifacts. On the genomic level, all exons of the CD95 gene including 20 or 30 bp of the adjacent introns and also the whole introns 5 and 6 were sequenced.
The most important primers for PCR and sequencing are given in tab. 1 and fig. 1 .
Flow cytometry determination of CD95 expression
PBMCs were prepared using lymphocyte separation medium (Gibco BRL, Eggenstein, Germany) and isolated by standard gradient centrifugation techniques followed by hypotonic lysis of remaining erythrocytes. After activation with10 µg/ml phytohemagglutinin (PHA, Sigma L9132) for 24hrs and different time intervals 
Apoptosis measurement by Flow-cytometry
PBMCs were incubated in PHA and later activated with IL2 for 5 days as described FITC-annexin binding to phosphatidyl serine, which turns to the outer cell membrane surface (green fluorescence), whereas cell death can be measured by propidium iodide, which stains the DNA of cells that lost its membrane integrity (red fluorescence). As agonistic antibodies the CH-11 IgM clone was used for diagnosis and when effectiveness in inducing apoptosis was essential whereas the Apo-1 antibody (ALEXIS Biochemicals Products) was used for graded responses.
Determination of the sCD95 secretion
PBMCs were incubated with PHA and activated with IL2 as described above for 0, 2 or 5 days. The medium containing IL2 was changed 48 hrs before measurement and the suspension was adjusted to 10 6 cells/ml. Aliquots of 50 µL of the cell supernatant were tested for sCD95 in appropriate dilutions using the MBL sCD95 (S) ELISA kit (No.5251, Medical and Biol. Laborat., Nagoya, Japan) through standard sandwich ELISA techniques. Measurements of CD95 expression, secretion of sCD95, apoptosis, and determination of the alternatively spliced forms of CD95 mRNA were also performed on optimally proliferating EBV-transformed B-cells without additional stimulation.
Incubation of Jurkat cells in serum or cells supernatant containing sCD95
Cells were incubated in 70% serum or supernatant and 30% standard medium before super CD95L was added. Apoptosis was measured 20 hrs later.
Plasmids and transfection
AU1-tagged CD95-encoding plasmid (pCI-backbone) has been used before 8 . AU1
tagged CD95-del6 (CD95∆TM) plasmid for sCD95 production was made by applying site directed mutagenesis to the original CD95 plasmid using the Stratagene QuikChange plasmid derived from bacteria was used as the template and both primers were added for an 18-cycle PCR, the remaining methylated template was digested with the Dpn I provided, and the PCR product was used to transform XL 10-Gold competent bacteria.
Bacterial colonies growing under appropriate selection were selected for further processing and correct plasmids were purified using the Marligen Biosciences Maxiprep system (Cat. 8µg/ml polybrene was added and the plate was centrifuged at 2500rpm for 20min. 96h
after transduction the efficiency was analyzed by flow cytometry and found to be more than 90%. sCD95 (sFas) expression of transduced Jurkat cells was analyzed by ELISA as described. The same type of calculation was used in all experiments where % cell loss is given.
Co-incubation assay of Jurkat and CD95L-L5178Y cells, and calculation of % cell loss

Case report
The family history of the patient is unremarkable. He presented with epistaxis, thrombocytopenia (min. 10,000/µl), splenomegaly, and cervical and axillary lymphoadenopathy at age 8 years. His mother reported that the splenomegaly had already been observed shortly after birth. From age 8 to 18, the patient had thrombocytopenia that was accompanied with petechia and hematomas of the skin once or twice a year. Lymph node biopsies were taken at age 10 and 12, both showing nonspecific, chronic inflammatory lymphatic hyperplasia. The patient also presented with recurrent neutropenia (250-600/µl). Anti-platelet autoantibodies were strongly positive and antineutrophil autoantibodies were weakly positive. Repeated cytological and histological examinations of the patient's bone marrow revealed an enhanced granulocytopoiesis and normal megakaryocytes. All other findings and all routine immunological diagnostics were unremarkable. The thrombopenia and neutropenia responded well to steroids, but autoantibodies did not.
At age 12, 80% of the patient's spleen was removed by surgery. However, it grew back to a moderately enlarged size within three years. Since age 18, the patient who is 24 years old now, has only had minor lymph node swellings and no further problems.
Platelet and leukocyte counts have always been normal ever since. The CD4, 8 -double negative T cells have been normal lately.
All other family members including the father are completely healthy and have never had any similar symptoms. The father and one daughter participate in sports and other physical strains along with their profession.
Results
The clinical phenotype of our patient (see case report) was typical for ALPS. We found that as compared with normal controls, the CD95-induced apoptosis was clearly reduced in the peripheral blood lymphocytes from the patient, from all family members with the respective mutation (figs. 1D, 2A, tab.2) and in EBV-B cells ( fig.2 B) from the patient. Since the majority of ALPS patients carry a mutation in the CD95 gene 6 , we sequenced the patient genomic and cDNA for CD95 gene . We found a C->G point mutation at position -3 of intron-5 in one allele, which led to an alteration of the splice cis regulatory region (cctacag/G->cctagag/G, fig.1 fig.1 D) . Therefore, the maternal allele does not contribute to the patient's ALPS, at least not critically.
We found that in healthy donor lymphocytes, the ratio of wild-type (wt-) versus CD95-del6 was increased after lymphocyte activation as shown in fig.3 . This confirms the previous observation that during lymphocyte activation, the splicing of complete wt-CD95 mRNA is normally upregulated 29 . However, we found that in the patient, the splicing variant CD95-del6 was upregulated above normal range during lymphocyte activation for both primary T and B cells, as well as in auto-proliferating EBV-B cell lines ( fig.3A, B-cells) . Our data suggests that the patient lymphocytes express an elevated amount of the alternatively spliced CD96-del6 mRNA during immune responses.
Next we investigated the impact of this variant splicing of CD95 on its cell surface expression. The full-length wt-CD95 mRNA is expressed as a membrane-bound, apoptosis-mediating receptor, which is capable of binding CD95L 32 . We found that after activation, the membrane CD95-expression on the patient PBMC was decreased as CD95-del6 mRNA splicing variants are translated to sCD95 proteins, which are secreted by lymphocytes. It has been postulated that the sCD95 can bind CD95L and thus antagonize CD95L-induced apoptosis 32 . In accordance with the excessive production of CD95-del6 mRNA in the patient's lymphocytes, an approximate of seven-fold increase in sCD95 was detected in the supernatant of the patient's cells ( fig.4 A, B) , and in the serum of all affected family members ( fig.4 D) ; as compared to that of the healthy control donors. The secretion of sCD95 was upregulated during activation of the patient lymphocytes ( fig.4 B) .
Next we evaluated the sCD95 at functional level. As mentioned above and shown in fig.2 (see also supplemental fig.1 ), the apoptosis of activated PBMCs from the patient and the other affected family members was obviously decreased as compared to control cells when these cells were stimulated by an agonistic anti-CD95 mAb CH-11 (or by super CD95L, data not shown), even though the induction of cell death was not abolished as seen in some ALPS patients previously described 6;22 . A similar reduction of CD95-induced apoptotic response was also observed in patient EBV-B cells ( fig.2 B) . This
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Since excessive concentrations of the multi-valent anti-CD95 failed to enhance apoptosis of the patient lymphocytes, we hypothesized that the decrease in expression of membrane-bound CD95, but not the sCD95 produced by patient cells accounts for the 
org From
The mouse thymoma BW cells have been successfully used to demonstrate dominant negative effects of mutations in the CD95 death domain 8 . Therefore, these cells were transfected with either wt-CD95 or CD95-del6 or both (and with empty plasmid as a control, fig.6 ). As shown in fig.6 C, the expression of wt-CD95 was necessary to render BW cells sensitive to apoptosis induced by specific anti-human CD95. However, the presence of human sCD95 did not interfere with the induction of apoptosis. Thus, in this co-expression model we found no inhibitory effect of sCD95.
To further explore the potential functions of sCD95 in apoptosis, we incubated Jurkat cells with different, at certain occasions extremely high, concentrations (10-1000ng/ml) of recombinant human (rh) sCD95, and induced apoptosis of the cultured cells by super CD95L ( fig.7 A) . We only observed modest inhibition of apoptosis at the highest concentration of rh sCD95, and yet the inhibition was easily reversible by a moderate increase in CD95L concentration. We obtained a similar result using activated peripheral T-cells from healthy donors ( fig.7 B) . In another experiment we induced apoptosis by effector cells expressing CD95L on their surface to evaluate if cell to cell contact was more sensitive to sCD95 than to apoptosis induced by soluble CD95L ( fig.7 C, D) .
However, again only modest inhibition of apoptosis at the highest concentration of rh sCD95 was detected ( fig.7 C) . This minor inhibition is statistically significant if all experiments are combined ( fig.7 A, B, C) . Nevertheless, these data do not reveal a potent blocking effect for sCD95. expression. In this case, the disease phenotype is inherited in a dominant mode with low penetrance.
We found that the lymphocytes from our patient were resistant to in vitro CD95- 
apoptosis. Thus, our data suggests that sCD95 is not potent in neutralizing CD95L for apoptosis induction.
Results using BW cells 8;22 ( fig.6 ), rh-sCD95, and target cells expressing sCD95
( fig.7 ) further strengthen our conclusion that the soluble receptor is not a very potent regulator of cell death under any condition tested. We therefore conclude that the regulatory and pathogenic function of sCD95 may have been overestimated 32;34;40-43 .
Our results strongly suggest that the transient ALPS of the patient in this family is caused by haploinsufficiency of membrane CD95, and that the increased sCD95 is of minor importance, if it has any effect at all, in causing the cellular resistance to CD95-induced apoptosis. The assumption of haploinsufficiency is supported by the observation of the decreased expression of wt-CD95 in patient cells; the reconstitution of normal CD95 mediated apoptosis by transfection of wt-CD95; the lack of significant interference on the wt-CD95 from the mutated allele; and the low penetrance in the family. As mentioned above, this low penetrance has previously been observed in other ALPS families with haploinsufficiency 7;14;22;39 . In accordance with these reports, we propose that a sufficient expression of full-length CD95 protein on lymphocyte membrane is crucial for keeping normal apoptosis responses to CD95 stimulation.
An important role for sCD95 has been hypothesized in malignant and autoimmune diseases 32;34;40-43 . However, in these reports, high concentrations were often used in the analysis of in vitro and in vivo functions of sCD95, and we confirm some 
